



Supplemental Figure 1



A



B




C




Supplemental Figure 2.

A




B






Supplemental Figure 3.

A




B




Supplemental Figure 4.

A




B



PV with Sustained Clinical Response (n=3), **black symbols**
PV with Relapse following CR (n=2), **red symbols**

Supplemental Figure 5.



Sustained Clinical Response (n=9), **black symbols**

No clinical response (n=1), **orange symbols**

Relapsing participants (n=2), **red symbols**

Supplemental Table 1. Summary of individual clinical and serological responses by participants from cohort 3 and 4 who achieved sustained clinical response

Participant	Diagnosis	PDAI activity			Anti-Dsg-1 titer (U/mL)			Anti-Dsg-3 titer (U/mL)		
		BL	EoT	EoS	BL	EoT	EoS	BL	EoT	EoS
1	PF	9	0	0	75	12	29	-	-	-
2	PV	27.6	3	2	79	ND	ND	380	168	316
3	PF	20.3	2.9	3	252	40	76	-	-	-
4	PF	34.5	3	0	444	ND	ND	-	-	-
5	PV	14.6	0	0	18	ND	ND	4440*	504	632
6	PV	11	3	1	-	-	-	728	232	276
7	PF	11.2	0	0	62	29	29	-	-	-
8	PV	10.3	1	0	69	ND	ND	920*	152	380
9	PF	19	1	0	700	115	652	52	ND	ND
10	PF	30.2	5.3	6.3	660	112	127	-	-	-
16	PV	2	1	1	-	-	-	171	103	84
17	PV	3	1	1	59	19	11	392	444	272
18	PV	12	1	2.6	-	-	-	-	-	-
20	PV	23	0	0	129	ND	ND	2208*	63	272
21	PV	18.9	0	0	252	151	80	1738*	452	412
22	PV	14	0	0	9	9	20	580	97	328

BL, baseline; EoT, end of treatment; EoS, end of study; ND, non-detectable; PDAI, pemphigus disease area index; PV, pemphigus vulgaris; PF, pemphigus foliaceus. *values determined in the research laboratory on leftover serum samples. During the trial 800 U/mL was upper limit of quantification.